NeoAdjuvant pembrolizumab and STEreotactic radiotherapy prior to nephrectomy for renal cell carcinoma (NAPSTER): A phase II randomised clinical trial

[1]  N. Girard,et al.  Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. , 2022, The New England journal of medicine.

[2]  S. Loi,et al.  Stereotactic Radiotherapy and Short-course Pembrolizumab for Oligometastatic Renal Cell Carcinoma-The RAPPORT Trial. , 2021, European urology.

[3]  F. Lohr,et al.  Nivolumab in Combination with Stereotactic Body Radiotherapy in Pretreated Patients with Metastatic Renal Cell Carcinoma. Results of the Phase II NIVES Study. , 2021, European urology.

[4]  Laurentiu M. Pop,et al.  Outcome and Immune Correlates of a Phase II Trial of High-Dose Interleukin-2 and Stereotactic Ablative Radiotherapy for Metastatic Renal Cell Carcinoma , 2021, Clinical Cancer Research.

[5]  J. Burke,et al.  Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[6]  S. Jain,et al.  Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. , 2021, The Lancet. Oncology.

[7]  B. Trock,et al.  Neoadjuvant Nivolumab in Patients with High-risk Nonmetastatic Renal Cell Carcinoma. , 2021, European urology oncology.

[8]  N. Girard,et al.  Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). , 2021 .

[9]  C. Porta,et al.  Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma. , 2021, The New England journal of medicine.

[10]  A. Hakimi,et al.  A pilot study of preoperative nivolumab in high-risk nonmetastatic renal cell carcinoma. , 2021 .

[11]  T. Powles,et al.  Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. , 2020, The Lancet. Oncology.

[12]  Anurag K. Singh,et al.  Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients , 2020, Proceedings of the National Academy of Sciences.

[13]  K. Bensalah,et al.  Immunotherapy in Renal Cell Carcinoma: The Future Is Now , 2020, International journal of molecular sciences.

[14]  D. Berry,et al.  Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. , 2020, JAMA oncology.

[15]  I. Kaplan,et al.  Stereotactic Ablative Radiotherapy for ≥T1b Primary Renal Cell Carcinoma: A Report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). , 2019, International journal of radiation oncology, biology, physics.

[16]  J. Manola,et al.  Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial. , 2020, The Journal of urology.

[17]  C. Porta,et al.  Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[18]  I. Kaplan,et al.  The Emerging Role of Stereotactic Ablative Radiotherapy for Primary Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. , 2019, European urology focus.

[19]  N. Agarwal,et al.  Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810). , 2019, Journal of Clinical Oncology.

[20]  Lorenzo Marconi,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update. , 2019, European urology.

[21]  Timothy K. Nguyen,et al.  Measuring the Integration of Stereotactic Ablative Radiotherapy Plus Surgery for Early-Stage Non–Small Cell Lung Cancer: A Phase 2 Clinical Trial , 2019, JAMA oncology.

[22]  S. Signoretti,et al.  The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? , 2019, Future oncology.

[23]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[24]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  Oliver Blanck,et al.  ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams , 2019, Strahlentherapie und Onkologie.

[26]  V. Khoo,et al.  TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II , 2018, BMC Cancer.

[27]  M. Casey,et al.  Axitinib versus placebo as an adjuvant treatment of renal cell carcinoma: results from the phase III, randomized ATLAS trial , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  Chengzhong Ye,et al.  Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis , 2018, Nature Medicine.

[29]  Bohuslav Melichar,et al.  Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal‐Cell Carcinoma , 2018, The New England journal of medicine.

[30]  N. Lawrentschuk,et al.  Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial , 2017, BJU international.

[31]  R. Motzer,et al.  Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Anurag K. Singh,et al.  A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma , 2017, Clinical Cancer Research.

[33]  K. Bensalah,et al.  European Association of Urology Guidelines Regarding Adjuvant Therapy for Renal Cell Carcinoma , 2016 .

[34]  J. Patard,et al.  Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy. , 2016, The New England journal of medicine.

[35]  J. Manola,et al.  Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial , 2016, The Lancet.

[36]  H. Onishi,et al.  Consensus statement Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma , 2016 .

[37]  C. Drake,et al.  Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen , 2014, Cancer Immunology Research.

[38]  I. Stratford,et al.  Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. , 2014, Cancer research.

[39]  R. Weichselbaum,et al.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. , 2014, The Journal of clinical investigation.

[40]  M. Rafi,et al.  Need for a new trial to evaluate postoperative radiotherapy in renal cell carcinoma: a meta-analysis of randomized controlled trials. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[41]  J. Lam,et al.  Surveillance following radical or partial nephrectomy for renal cell carcinoma , 2005, Current urology reports.

[42]  R. Figlin,et al.  Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. , 2003, The Urologic clinics of North America.

[43]  R. Figlin,et al.  Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.